[New therapies for spastic movement disorders].
Benecke
Reiner
R
Klinik und Poliklinik für Neurologie, Universität Rostock. robert.patejdl@uni-rostock.de
Patejdl
Robert
R
D000284:Administration, Oral; D001418:Baclofen / Q000009:adverse effects / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use; D002186:Cannabinoids / Q000009:adverse effects / Q000627:therapeutic use; D003000:Clonidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D003975:Diazepam / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D007278:Injections, Spinal; D009069:Movement Disorders / Q000209:etiology / Q000534:rehabilitation*; D009125:Muscle Relaxants, Central / Q000009:adverse effects / Q000627:therapeutic use; D009128:Muscle Spasticity / Q000209:etiology / Q000534:rehabilitation*; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D014049:Tolperisone / Q000009:adverse effects / Q000627:therapeutic use
D002186:Cannabinoids; D009125:Muscle Relaxants, Central; D010276:Parasympatholytics; C023754:tizanidine; D019274:Botulinum Toxins, Type A; D014049:Tolperisone; D001418:Baclofen; D003000:Clonidine; D003975:Diazepam